Griffith University and Pfizer in new partnership to unlock nature’s cure for infections
A study in the Dec. 15 issue of the Journal of Clinical Sleep Medicine suggests that screening type 2 diabetes patients for obstructive sleep apnea (OSA) and treating those who have OSA with continuous positive airway pressure (CPAP) therapy could improve the management of their hyperglycemia and might favorably influence their long-term prognosis. Results
Full Post: Continuous positive airway pressure improves sleeping glucose levels in type 2 diabetics with obstructive sleep apnea
In the quest to develop the next generation of anti-infective medicine, Griffith University and Pfizer, the world’s largest research-based pharmaceutical company, announced a leading partnership today.
Griffith University’s Eskitis Institute for Cell and Molecular Therapies investigates novel drug- and cell-based therapies for human diseases in the areas of cancer, infection and immunity, neglected diseases, neurological disease and stem cell biology. The Institute’s research includes a program to search for new compounds from nature that could be developed into drugs.
Eskitis Institute Director Professor Ronald Quinn, who is leading the project, said Pfizer’s commitment to develop nature-based drugs was a clear demonstration of confidence by a major pharmaceutical company in the continuing promise of natural products as a source of drugs.
“This is an exciting partnership for the Institute and we are looking forward to developing novel anti-infective medicine by screening the Institute’s extensive collection of natural products,” Professor Quinn said.
Professor Quinn and his team have spent the past 14 years developing “Nature Bank”, a unique library of 200,000 natural product fractions derived from a collection of over 40,000 samples of plants and marine invertebrates collected from mega-diverse areas of tropical Queensland, the Great Barrier Reef, Tasmania, Papua New Guinea and China.
Nature Bank contains drug-like molecules separated into mixtures of a small number of compounds. This allows the rapid Identification of the active molecules from bioactive fractions using modern chemical methods.
“Previously, natural product discovery had notoriously slow timelines as it relied on an iterative bio-assay guided isolation strategy. We are now able to rapidly identify promising compounds in Nature Bank.”
Dr Daniel Grant, Head of Strategic Alliances at Pfizer Australia said that this alliance is a unique opportunity to gain access to a truly unique library of natural products. “Pfizer hopes that this will be the first of several screening campaigns to be run in conjunction with Griffith University which will facilitate our drug discovery programs.”
“Working with Australian researchers and institutes only affirms Pfizer’s global position of working with the best talent regardless of where they are in the world,” added Dr Grant.
Pfizer Australia has committed to spending more than $50million in 2008 on various R&D initiatives in Australia including research grant, clinical trials and a $3.5million program for the Pfizer Research Fellows.
Griffith University will receive payments based on drug development milestones and royalties based on sales of the anti-infective medicines that will be developed by Pfizer.
Bacteria cause a range of infectious diseases, including tuberculosis and many food-borne diseases, killing millions around the world.
Bolder BioTechnology, Inc. today announced that it has been awarded a $1.9 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant will be used to perform additional preclinical toxicology and pharmacology studies of the company’s proprietary
Full Post: Bolder BioTechnology awarded NIH grant to continue development of growth hormone product
Pfizer Inc. has agreed to provide the University of Rochester Medical Center (URMC) with a unique set of electrocardiographic data that will help researchers develop new methods to ensure the safety of experimental drugs. This is the first time a major pharmaceutical company has agreed to publicly share anonymous data from one of its drug
Full Post: Pfizer joins URMC initiative for safety of experimental drugs
The U.S. Food and Drug Administration today announced the launch of a voluntary pilot program that would help promote the safety of drugs and active drug ingredients produced outside the United States. The FDA plans to select 100 applicants to participate in the Secure Supply Chain pilot program. To qualify, applicants will need to
Full Post: FDA launches pilot program to improve drug safety and active drug ingredients produced outside U.S.
Virginia Tech Intellectual Properties (VTIP) announces that the US Patent and Trademark Office has granted a patent for targets and methods to develop new drugs for malaria. For decades, scientists have been searching for a way to target malaria-causing parasites that have infected the human body. Researchers from the Virginia Biotechnology Institute (VBI) at Virginia
Full Post: U.S. patents granted to Virginia Tech for targets and methods to develop new drugs for malaria
neuMirRx Corp today welcomed the issuance of U.S. patent 7,345,093, entitled “Methods for Enhancing Solubility of Compounds” which covers novel formulation methods to enhance the solubility of hydrophobic compounds. The rights to this patent and related proprietary technology, the neuNanoParticle™, have been obtained by neuMirRx Corp through an exclusive license arrangement with Formatech, Inc.
Full Post: neuMirRx issued U.S. patent for “methods for enhancing solubility of compounds